PMID- 25528388
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20240213
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Print)
IS  - 1083-8791 (Linking)
VI  - 21
IP  - 3
DP  - 2015 Mar
TI  - Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia 
      with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or 
      total body irradiation.
PG  - 552-8
LID - S1083-8791(14)01410-4 [pii]
LID - 10.1016/j.bbmt.2014.12.010 [doi]
AB  - Cyclophosphamide (Cy) in combination with busulfan (Bu) or total body irradiation 
      (TBI) is the most commonly used myeloablative conditioning regimen in patients 
      with chronic myeloid leukemia (CML). We used data from the Center for 
      International Bone Marrow Transplantation Research to compare outcomes in adults 
      who underwent hematopoietic cell transplantation for CML in first chronic phase 
      after myeloablative conditioning with Cy in combination with TBI, oral Bu, or 
      intravenous (i.v.) Bu. Four hundred thirty-eight adults received human leukocyte 
      antigen (HLA)-matched sibling grafts and 235 received well-matched grafts from 
      unrelated donors (URD) from 2000 through 2006. Important differences existed 
      between the groups in distribution of donor relation, exposure to tyrosine kinase 
      inhibitors, and year of transplantation. In multivariate analysis, relapse 
      occurred less frequently among patients receiving i.v. Bu compared with TBI 
      (relative risk [RR], .36; P = .022) or oral Bu (RR, .39; P = .028), but 
      nonrelapse mortality and survival were similar. A significant interaction was 
      detected between donor relation and the main effect in leukemia-free survival 
      (LFS). Among recipients of HLA-identical sibling grafts, but not URD grafts, LFS 
      was better in patients receiving i.v. Bu (RR, .53; P = .025) or oral Bu (RR, .64; 
      P = .017) compared with TBI. In CML in first chronic phase, Cy in combination 
      with i.v. Bu was associated with less relapse than TBI or oral Bu. LFS was better 
      after i.v. or oral Bu compared with TBI.
CI  - Copyright (c) 2015 American Society for Blood and Marrow Transplantation. Published 
      by Elsevier Inc. All rights reserved.
FAU - Copelan, Edward A
AU  - Copelan EA
AD  - Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina. 
      Electronic address: Heather.T.Johnson@carolinashealthcare.org.
FAU - Avalos, Belinda R
AU  - Avalos BR
AD  - Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina.
FAU - Ahn, Kwang Woo
AU  - Ahn KW
AD  - Division of Biostatistics, Institute for Health and Society, Medical College of 
      Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Center for International 
      Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, 
      Wisconsin.
FAU - Zhu, Xiaochun
AU  - Zhu X
AD  - Department of Medicine, Center for International Blood and Marrow Transplant 
      Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
FAU - Gale, Robert Peter
AU  - Gale RP
AD  - Division of Experimental Medicine, Department of Medicine, Hematology Research 
      Centre, Imperial College of London, London, United Kingdom.
FAU - Grunwald, Michael R
AU  - Grunwald MR
AD  - Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina.
FAU - Hamadani, Mehdi
AU  - Hamadani M
AD  - Department of Medicine, Center for International Blood and Marrow Transplant 
      Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
FAU - Hamilton, Betty K
AU  - Hamilton BK
AD  - Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio.
FAU - Hale, Gregory A
AU  - Hale GA
AD  - Department of Hematology/Oncology, All Children's Hospital, St Petersburg, 
      Florida.
FAU - Marks, David I
AU  - Marks DI
AD  - University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
FAU - Waller, Edmund K
AU  - Waller EK
AD  - Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
FAU - Savani, Bipin N
AU  - Savani BN
AD  - Division of Hematology/Oncology, Department of Medicine, Vanderbilt University 
      Medical Center, Nashville, Tennessee.
FAU - Costa, Luciano J
AU  - Costa LJ
AD  - Division of Hematology/Oncology, Department of Medicine, Medical University of 
      South Carolina, Charleston, South Carolina.
FAU - Ramanathan, Muthalagu
AU  - Ramanathan M
AD  - Division of Hematology Oncology, UMass Memorial Medical Center, Worcester, 
      Massachusetts.
FAU - Cahn, Jean-Yves
AU  - Cahn JY
AD  - Department of Hematology, University Hospital, Grenoble, France.
FAU - Khoury, H Jean
AU  - Khoury HJ
AD  - Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
FAU - Weisdorf, Daniel J
AU  - Weisdorf DJ
AD  - Division of Hematology, Oncology and Transplantation, Department of Medicine, 
      University of Minnesota Medical Center, Minneapolis, Minnesota.
FAU - Inamoto, Yoshihiro
AU  - Inamoto Y
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
FAU - Kamble, Rammurti T
AU  - Kamble RT
AD  - Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor 
      College of Medicine, Houston, Texas.
FAU - Schouten, Harry C
AU  - Schouten HC
AD  - Divison of Hematology, Academische Ziekenhuis Maastricht, Maastricht, 
      Netherlands.
FAU - Wirk, Baldeep
AU  - Wirk B
AD  - Department of Internal Medicine, Stony Brook University Medical Center, Stony 
      Brook, New York.
FAU - Litzow, Mark R
AU  - Litzow MR
AD  - Department of Hematology, Mayo Clinic, Rochester, Minnesota.
FAU - Aljurf, Mahmoud D
AU  - Aljurf MD
AD  - Department of Oncology, King Faisal Specialist Hospital Center & Research, 
      Riyadh, Saudi Arabia.
FAU - van Besien, Koen W
AU  - van Besien KW
AD  - Department of Medical Oncology, Weill Cornell Medical College, New York, New 
      York.
FAU - Ustun, Celalettin
AU  - Ustun C
AD  - Division of Hematology, Oncology and Transplantation, Department of Medicine, 
      University of Minnesota Medical Center, Minneapolis, Minnesota.
FAU - Bolwell, Brian J
AU  - Bolwell BJ
AD  - Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio.
FAU - Bredeson, Christopher N
AU  - Bredeson CN
AD  - The Ottawa Hospital Blood & Marrow Transplant Program and the Ottawa Hospital 
      Research Institute, Ottawa, ON, Canada.
FAU - Fasan, Omotayo
AU  - Fasan O
AD  - Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina.
FAU - Ghosh, Nilanjan
AU  - Ghosh N
AD  - Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina.
FAU - Horowitz, Mary M
AU  - Horowitz MM
AD  - Department of Medicine, Center for International Blood and Marrow Transplant 
      Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
FAU - Arora, Mukta
AU  - Arora M
AD  - Division of Hematology, Oncology and Transplantation, Department of Medicine, 
      University of Minnesota Medical Center, Minneapolis, Minnesota.
FAU - Szer, Jeffrey
AU  - Szer J
AD  - Department of Clinical Haematology and Bone Marrow Transplantation, Royal 
      Melbourne Hospital, Parkville, Victoria, Australia.
FAU - Loren, Alison W
AU  - Loren AW
AD  - Division of Hematology/Oncology, Department of Medicine, Perelman School of 
      Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Alyea, Edwin P
AU  - Alyea EP
AD  - Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts.
FAU - Cortes, Jorge
AU  - Cortes J
AD  - Division of Cancer Medicine, Department of Leukemia, The University of Texas M.D. 
      Anderson Cancer Center, Houston, Texas.
FAU - Maziarz, Richard T
AU  - Maziarz RT
AD  - Center for Hematologic Malignancies, Oregon Health and Science University, 
      Portland, Oregon.
FAU - Kalaycio, Matt E
AU  - Kalaycio ME
AD  - Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio.
FAU - Saber, Wael
AU  - Saber W
AD  - Department of Medicine, Center for International Blood and Marrow Transplant 
      Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
LA  - eng
GR  - 5U01HL069294/HL/NHLBI NIH HHS/United States
GR  - U24 CA076518/CA/NCI NIH HHS/United States
GR  - U24-CA76518/CA/NCI NIH HHS/United States
GR  - U01 HL069294/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20141217
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Myeloablative Agonists)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - G1LN9045DK (Busulfan)
SB  - IM
MH  - Administration, Intravenous
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Allografts
MH  - Busulfan/*administration & dosage
MH  - Cyclophosphamide/*administration & dosage
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality/therapy
MH  - Male
MH  - Middle Aged
MH  - Myeloablative Agonists/*administration & dosage
MH  - Siblings
MH  - Survival Rate
MH  - *Transplantation Conditioning
MH  - Whole-Body Irradiation
PMC - PMC4329042
MID - NIHMS650721
OTO - NOTNLM
OT  - Busulfan
OT  - Chronic myeloid leukemia
OT  - Total body irradiation
EDAT- 2014/12/22 06:00
MHDA- 2015/10/27 06:00
PMCR- 2016/03/01
CRDT- 2014/12/22 06:00
PHST- 2014/08/12 00:00 [received]
PHST- 2014/12/10 00:00 [accepted]
PHST- 2014/12/22 06:00 [entrez]
PHST- 2014/12/22 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - S1083-8791(14)01410-4 [pii]
AID - 10.1016/j.bbmt.2014.12.010 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2015 Mar;21(3):552-8. doi: 
      10.1016/j.bbmt.2014.12.010. Epub 2014 Dec 17.